Rockville's Vigene Biosciences closes $292M deal to be acquired
Charles River Laboratories International Inc. (NYSE: CRL) said Tuesday morning it had completed its acquisition of Vigene Biosciences Inc., a Rockville firm that helps gene therapy and vaccine companies develop and manufacture products for rare diseases.
Massachusetts-based Charles River paid $292.5 million for Vigene, and it said the purchase price could include up to $57.5 million in additional payments contingent on future performance.
When the deal was first announced in May, Charles River…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Drew Hansen Source Type: news
More News: Gene Therapy | Genetics | Health Management | Mergers and Aquisitions | Pharmaceuticals | Rare Diseases | Vaccines